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Abstract
Background:  The CO/NO-cGMP signalling system participates in the regulation of many
physiological processes. The roles this system plays in spinal cord nociceptive signalling are
particularly important. While individual components have been examined in isolation, little study
has been dedicated to understanding the regulation and functioning of the system as a whole.
Results: In these studies we examined the time course of expression of 13 genes coding for
components of this system including isoforms of the heme oxygenase (HO), nitric oxide synthase
(NOS), soluble guanylate cyclase (sGC), cGMP dependent protein kinase (PKG) and
phosphodiesterase (PDE) enzyme systems. Of the 13 genes studied, 11 had spinal cord mRNA
levels elevated at one or more time points up to 48 hours after hindpaw formalin injection. Of the
11 with elevated mRNA, 8 had elevated protein levels 48 hours after formalin injection when
mechanical allodynia was maximal. No component had an increased protein level which did not
have an increased mRNA level at one or more time points. Injection of morphine 10 mg/kg prior
to formalin completely abolished the acute nociceptive behaviours, but did not alter the degree of
sensitivity which developed in the formalin treated hind paws during the subsequent 48 hours.
Morphine treatment did, however, eliminate formalin induced increases in enzyme protein levels.
Conclusion: Our results indicate that the expression of the components of the CO/NO-cGMP
signalling system seems to be coordinated in such a way that a generalized multi-level enhancement
rather than a tightly limited step specific response occurs with noxious stimulation. Furthermore,
the analgesic morphine administered prior to noxious stimulation can prevent long-term changes
in gene expression though not necessarily nociceptive sensitisation.
Background
Traditional approaches to the study of nociceptive signal-
ing mechanisms often focus on single gene products. The
functions of such molecules are commonly examined
using pharmacological, electrophysiological, genetic and
behavioural techniques. While there is little doubt that
these investigations have been of substantial utility in
understanding nociceptive signaling, it is widely appreci-
ated that nociceptive signaling involves systems of inter-
acting component molecules rather than individual
molecules functioning independently. Furthermore,
experimental paradigms are often optimised to highlight
the roles of the molecules of interest making it difficult to
integrate the existing literature towards a better under-
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standing of how signaling system components function
together under a single well defined set of parameters.
The analysis of changes in gene expression in models of
pain is one type of paradigm often used to infer participa-
tion of a gene product in nociceptive signaling. Unfortu-
nately, examination of the existing literature reveals the
use of different species, strains, types of noxious stimula-
tion, tissues analysed, time courses, mRNA versus protein
measurement and other methods of analysis. Few studies
have carefully examined changes in gene expression for
large sets of genes coding for the many members of noci-
ception-related signaling pathways.
The spinal cord CO/NO-cGMP signaling system is one of
the best studied nociceptive signaling systems, and the
available reports demonstrate some of the issues intro-
duced above. The monoxides CO and NO are produced
by heme oxygenase (HO) and nitric oxide synthase (NOS)
respectively. The roles of HO in many pain models have
been examined with changes in the expression of the spi-
nal cord HO-2 isoform reported for both neuropathic and
incisional pain models, though always studied apart from
other CO/NO-cGMP signaling system components [1-4].
Likewise for NOS, increases in the spinal cord expression
Alterations in expression of HO isoforms after the hind paw  injection of formalin Figure 2
Alterations in expression of HO isoforms after the hind paw 
injection of formalin. Panel A provides a time course analysis 
of changes in levels of HO-1 mRNA up to 48 hours after for-
malin injection relative to controls. Panel B summarizes 
measurements for HO-2 mRNA. Data are presented as 
mean values +/- S.E.M, *p < 0.05, **p < 0.01, ***p < 0.001.
Nociceptive behaviours displayed after formalin injection Figure 1
Nociceptive behaviours displayed after formalin injection. In 
panel A the nociceptive behaviour of mice is presented as the 
total number of seconds spent licking in 5 minute intervals 
beginning with the injection of formalin. Some mice were 
pre-treated with a 10 mg/kg injection of morphine. In panel 
B, the time course of formalin-induced mechanical allodynia 
with and without morphine pre-treatment is displayed. 
Mechanical withdrawal thresholds were followed using von 
Frey fibers. Data are presented as mean licking times or 
thresholds +/- SEM, **p < 0.01.Molecular Pain 2005, 1:33 http://www.molecularpain.com/content/1/1/33
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of nNOS I, iNOS and eNOS have been reported after nox-
ious stimulation of various types. In 2 reports 2 NOS spe-
cies were studied simultaneously after a noxious
inflammatory stimulus with Wu et al. reporting increased
spinal cord expression of nNOS and iNOS after capsaicin
injection [5], but Tao et al. reporting increased expression
of nNOS but not iNOS after carrageenan injection [6].
Once produced, these monoxides converge on guanylate
cyclase to stimulate the production of cGMP. For soluble
Alterations in expression of sGC isoforms after the hind paw  injection of formalin Figure 4
Alterations in expression of sGC isoforms after the hind paw 
injection of formalin. Panel A provides a time course analysis 
of changes in levels of sGCα1 mRNA up to 48 hours after 
formalin injection relative to controls. Panel B summarizes 
these measurements for sGCα2 mRNA. Data are presented 
as mean values +/- S.E.M, *p < 0.05, **p < 0.01, ***p < 0.001.
Alterations in expression of NOS isoforms after the hind  paw injection of formalin Figure 3
Alterations in expression of NOS isoforms after the hind 
paw injection of formalin. Panel A provides a time course 
analysis of changes in levels of nNOS mRNA up to 48 hours 
after formalin injection relative to controls. Panels B and C 
summarize measurements for iNOS and eNOS mRNA 
respectively. Data are presented as mean values +/- S.E.M, *p 
< 0.05, **p < 0.01, ***p < 0.001.Molecular Pain 2005, 1:33 http://www.molecularpain.com/content/1/1/33
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guanylate cyclase, type 1α (sGC1α), up-regulation in a
model of inflammatory pain has been described, though
other isoforms are not well studied [7]. The presumed tar-
get of cGMP is cGMP dependent protein kinase (PKG).
PKG1α undergoes up-regulation in spinal cord tissue
though PKG1β and PKG II expression do not appear to
have been studied [8,9]. Finally, various phosphodieste-
rases (PDE's) can metabolise cGMP thus terminating its
signaling functions, but we could identify no studies fol-
lowing the spinal cord expression of these enzymes in any
model of pain. Basal expression of PDE2,3 and 5 has been
demonstrated in spinal cord tissue [10,11].
Thus while the data pertaining to gene expression for
some CO/NO-cGMP signaling system components and
the large number of pharmacological studies not cited
above support roles for this system in nociceptive signal
transmission, few studies have attempted to follow the
expression of the various components under standardized
conditions. Such data would be useful in understanding
how the system may be regulated as a whole in the setting
of a specific type of pain. When 10 components of the spi-
nal cord CO/NO-cGMP signaling system were studied
together during the chronic exposure of mice to mor-
phine, it was observed that 7 of the components were up-
regulated in a coordinated fashion [12], thus coordina-
tion of expression in a nociceptive system seems plausi-
ble. The studies outlined below follow the expression of a
set of 13 genes coding for the various components of the
spinal cord CO/NO-cGMP signaling system over time in
the formalin model of inflammatory pain.
Results
Formalin testing
To characterize the spontaneous pain behaviors and per-
sistent mechanical allodynia associated with the hindpaw
injection of formalin in the C57Bl/6J mice used in subse-
quent experiments, we first measured the total times spent
licking the injected hind paws after formalin injection.
The phase I (0–5 min) average licking behavior was 65 +/
- 10 sec, and the total phase II (10–40 min) average was
179 +/- 20 sec similar to the observations reported earlier
by our laboratory [2] (Figure 1A). The administration of
10 mg/kg morphine prior to formalin injection nearly
completely eliminated formalin-induced licking behav-
iors during phase I and phase II.
In Figure 1B data from experiments in which mechanical
von Frey withdrawal thresholds were measured in mice up
to 48 hours after formalin injection are presented. This
mechanical nociceptive sensitization is a more chronic
consequence of formalin injection than the phase I and II
licking behavior. The mechanical thresholds in the forma-
lin injected mice were significantly lower than those
observed in saline-injected animals at all time points after
Alterations in expression of PKG isoforms after the hind paw  injection of formalin Figure 5
Alterations in expression of PKG isoforms after the hind paw 
injection of formalin. Panel A provides a time course analysis 
of changes in levels of PKG1α mRNA up to 48 hours after 
formalin injection relative to controls. Panels B and C sum-
marize measurements for PKG 1β and PKG II mRNA respec-
tively. Data are presented as mean values +/- S.E.M, *p < 
0.05, **p < 0.01, ***p < 0.001.Molecular Pain 2005, 1:33 http://www.molecularpain.com/content/1/1/33
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formalin injection (P < 0.01), and the allodynia was rela-
tively stable over this 48 hour time course. The adminis-
tration of morphine did not significantly alter the
measured allodynia over this time course.
Expression of components of the CO/NO-cGMP signaling 
system – mRNA
To examine possible changes in expression in the various
components of the CO/NO-cGMP signaling system, we
harvested lumbar spinal cord tissue at time points up to
48 hours after formalin injection. In Figure 2, 3, 4, 5, 6 the
time courses of spinal cord expression of these genes are
displayed. The components of the CO/NO-cGMP signal-
ing system were grouped into HO isoforms (Figure 2),
NOS isoforms (Figure 3), sGC isoforms (Figure 4), PKG
isoforms (Figure 5), and PDE isoforms (Figure 6). Each of
these groups had at least one member showing increased
expression during the period of observation. In fact, 11/13
components had an increased mRNA level measured at
one or more time points. There was no consistent tempo-
ral pattern for these increases in expression, though the
final 48 hour time point was the most common one (8/13
genes) for increased expression to be observed while the 8
hour time point was the point least likely (0/13 genes) to
be associated with increased expression. For only one
gene was there observed to be a significantly decreased
mRNA level at any time point (iNOS), and this was
observed only at 8 hours post formalin injection. For no
gene did saline injection significantly change expression
at any time point analyzed (data not shown).
Expression of components of the CO/NO-cGMP signaling 
system – protein
With the mRNA measurements in hand we turned to the
issue of whether the changes in message level corre-
sponded to changes in actual protein content in spinal
cord tissue. Table 2 provides a summary of the protein
measurements, and Figure 7 shows the appearance of the
bands observed on immunoblots. We chose for these
studies the 2 hour time point because we desired to meas-
ure possible protein level changes in the acute period fol-
lowing nociceptive behaviors. We hypothesized that no
protein level changes would be observed this close to the
time of formalin injection. The 48 hour time point was
chosen because our pervious studies had shown that spi-
nal cord protein accumulation lagged behind mRNA level
changes after hindpaw formalin stimulation [13], and our
primary interest was in the changes in protein content that
might support the persistent mechanical allodynia charac-
teristic of this pain model. Of the 11 genes displaying an
increase in mRNA at one or more time points, none dis-
played a greater protein level 2 hours after formalin injec-
tion. However, 8 were observed to have an increased
spinal content of protein at 48 hours after formalin injec-
tion. For one protein (PDE3) we were not able to opti-
Alterations in expression of PDE isoforms after the hind paw  injection of formalin Figure 6
Alterations in expression of PDE isoforms after the hind paw 
injection of formalin. Panel A provides a time course analysis 
of changes in levels of PDE 2 mRNA up to 48 hours after for-
malin injection relative to controls. Panels B and C summa-
rize measurements for PDE 3 and PDE 5 mRNA respectively. 
Data are presented as mean values +/- S.E.M, *p < 0.05, **p < 
0.01, ***p < 0.001.Molecular Pain 2005, 1:33 http://www.molecularpain.com/content/1/1/33
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mize our assay sufficiently to allow reliable detection
despite the use of multiple antibodies and assay condi-
tions. The 2 genes not having an increased mRNA level at
any time point studied also had no increase in protein at
48 hours post formalin injection. The analysis of samples
from morphine treated mice revealed that morphine treat-
ment prior to formalin injection eliminated the changes
in protein expression seen at 48 hours (Table 2).
Discussion
The spinal cord CO/NO-cGMP system has received much
attention, and is thought to regulate both nociceptive and
analgesic pathways. The existing published studies are sig-
nificantly limited, however. These limitations include, 1)
the study of single molecules to infer roles for the much
more complex enzymatic pathway, 2) the use of multiple
species and multiple strains of individual species making
the results of separate studies difficult to interpret
together, and 3) the arbitrary lack of examination of many
of this pathway's enzyme isoforms.
In the present studies we attempted to include the major-
ity of CO/NO-cGMP signaling system components in a
time course study following the levels of spinal cord
expression of corresponding genes in a commonly used
model of inflammatory pain. Overall, at each CO/NO-
cGMP system enzymatic level, we identified at least one
gene having correspondingly elevated mRNA and protein
levels after formalin injection. The principal observations
of our studies were, 1) C57Bl/6J mice display not only
robust phase I/II licking behaviour after formalin injec-
tion, but also a long lasting mechanical allodynia, 2) the
majority of the CO/NO-cGMP genes selected for study
had correspondingly elevated mRNA levels at some time
point within 48 hours of formalin injection, 3) of the
genes showing increased mRNA levels at some time point,
most of those had correspondingly elevated protein levels
as measured in spinal cord homogenates collected 48
hours after formalin injection, and 4) pre-treatment with
the analgesic morphine eliminated the acute nociceptive
response to formalin injection as well as the delayed
changes in spinal cord protein expression, but not chronic
Table 1: Summary of primer sequences and antibodies used. The sequence of forward (F) and reverse (R) primers used in PCR 
experiments are provided along with product sizes. Also provided are the sources for antibodies used and the dilution ranges.
Gene Primer Sequences Product Size Antibody Source, Cat# Dilution Range
HO-1 F:ACGCATATACCCGCTACCTG 227 Oncogene, PC340 1:100–1:500
R:GAAGGCGGTCTTAGCCTCTT
HO-2 F:ACTGAAGAAGGTTGCCCAGA 179 Santa Cruz, SC17786 1:100–1:500
R:CTTTATTGGCCTCCTCCACA
nNOS F:TCAGTCTCCCAGGCTAATGG 200 Santa Cruz, SC5302 1:200–1:1000
R:CTGTCCACCTGGATTCCTGT
iNOS F:CTCACTGGGACAGCACAGAA 199 Santa Cruz, SC650 1:200–1:500
R:TGGTCAAACTCTTGGGGTTC
eNOS F:CTCACTGGGACAGCACAGAA 199 Santa Cruz, SC8311 1:200–1:1000
R:TGGTCAAACTCTTGGGGTTC
sGCα1 F:AGCGACTGAACCTTGCACTT 119 Sigma, G4280 1:1000–1:2000
R:ACCTGCTGCAATTGCTTCTT
sGCα2 F:CGAAAGCAACTTCGATGTGA 120 Santa Cruz, SC20954 1:100–1:400
R:AAATGGGGTGGACAATCGTA
PKG Iα F:AAGCATGATGGGAAAACAGG 184 Santa Cruz SC10335 1:100–1:400
R:GTGACTGCTGGCTTGTGGTA
PKG Iβ F:GACAGCTGCATCATCAAGGA 198 Stressgen KAP-PK002 1:500–1:1500
R:GATGGCCCAGAGTTTCACAT
PKG II F:TGAACCGTGACGATGAAAAA 186 Santa Cruz SC25430 1:200–1:500
R:CAAGCTCCACTCTTCCGAAC
PDE 2 F:TTCAAGCTGCTGCAAGAAGA 224 Santa Cruz SC17227 1:200–1:1000
R:TTCCTGAGGACCTGGATACG
PDE 3 F:TTGCATAATTCAATGCCAAG 143 Multiple Multiple
R:TAGGTCCCGATCTTTTGCTG
PDE 5 F:AAATGGTGGGACCTTCACTG 201 Cell Signaling 4072 1:200–1:1000
R:GTGGCCGCTATCTTCTTCAGMolecular Pain 2005, 1:33 http://www.molecularpain.com/content/1/1/33
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nociceptive sensitisation. Figure 8 provides a diagram of
the CO/NO-cGMP signaling system highlighting the prin-
cipal enzymatic steps.
These observations of changes in expression do not by
themselves constitute comprehensive evidence of partici-
pation in inflammatory pain for each gene. However, our
observations do support the hypothesis that within the
spinal cord multi-level changes in CO/NO-cGMP system
gene expression follow noxious stimulation. Previously
provided pharmacological evidence demonstrates the par-
ticipation of HO [2,3], NOS [14,15], sGC [7] and PKG
[8,9] in at least the acute phases of formalin stimulation.
PDE inhibitors did not change acute formalin-induced
pain behaviours in one study, though those investigations
did not look at effects on persistent allodynia or changes
in expression [10]. Also, HO-2 null mutants have reduced
acute phase licking behaviour and long term allodynia
after formalin injection [13], nNOS null mutants have
normal formalin-induced licking but lack sensitivity to a
NOS inhibitor, and PKG I null mutants have reduced for-
malin-induced licking behaviour [16]. Previous pharma-
cological and genetic studies provide valuable evidence
concerning the functioning of the various individual com-
ponents in support of nociceptive signaling. The present
data, however, force us to consider the CO/NO-cGMP sys-
tem as a functional unit with multiple components
responding with some degree of coordination.
In the Background section several papers from the existing
literature were cited which in various rodent pain models
documented alterations in the expression of some of these
genes. Though our results are largely consistent with the
existing literature, there were differences between the
present data and those provided in previous reports using
similar paradigms. For example, 2 other groups have
reported changes in PKG1α expression after hindpaw for-
malin injection where we found none [8,9]. Rather, the
PKG II isoform seemed to have more robust changes in
both mRNA and protein levels in our hands. The use of
different species, rats versus mice, provides one possible
explanation for the differences in observations. None-the-
less, such differences highlight the importance of signal-
ing system components being studied simultaneously if
possible to eliminate model, strain and laboratory specific
factors from confounding interpretation of the results as
may occur when comparing results from the disparate
existing literature.
Our morphine data were particularly helpful in under-
standing the mechanisms governing the control of expres-
sion of the CO/NO-cGMP system genes and the
consequences of the enhanced expression. It was observed
that the injection of a dose of morphine prior to formalin
injection providing no more than 2 hours of analgesia in
these mice [17] eliminated the wide-spread enhancement
of expression of CO/NO-cGMP system genes. Thus it
appears both that 1) the enhanced expression of CO/NO-
cGMP system genes requires the intense acute nociception
characteristic of formalin injection, and 2) that long term
hind paw sensitisation does not require enhanced expres-
sion of these genes. This is not to say that the enzymatic
activity of the existing proteins was not altered. Likewise,
abundant pharmacological data indicates that some
degree of activity of the CO/NO-cGMP system is required
to support nociceptive sensitisation caused by formalin
administration. Yet, it is clear that the simple observation
of enhanced gene expression occurring in the context of
increased pain sensitivity does not prove the enhanced
Immunoblots for selected CO/NO-cGMP signaling system  proteins Figure 7
Immunoblots for selected CO/NO-cGMP signaling system 
proteins. Spinal cord protein samples from control animals 
(left hand lanes) and animals treated 48 hours previously with 
formalin (right hand lanes) are displayed for the 8 proteins 
found to display elevated expression at this time point. The 
molecular weights of the proteins are displayed next to the 
bands. After processing for CO/NO-cGMP signaling system 
proteins, blots were stripped and incubated with anti-actin 
antibodies in order to normalize for protein loading differ-
ences. The results of one such actin immunoblot is presented 
in the lower part of the figure.
Diagrammatic representation of the CO/NO-cGMP signaling  system Figure 8
Diagrammatic representation of the CO/NO-cGMP signaling 
system.
Target
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expression is required for that increased sensitivity. In the
formalin model the changes in gene expression might be
considered indicators of the gene product's involvement
in nociceptive signaling, not evidence for the necessity of
an increase in gene expression in order for nociceptive
sensitisation to occur. Also, though several of the genes
studied are most prominently expressed in sensory
processing areas of spinal cord dorsal horn tissue, e.g. HO-
2 [3], more focused investigations looking at the precise
spinal cord areas of altered gene expression may help us
to more precisely define the function of those changes.
The changes in gene expression we observed might be
related to influencing processes other than nociception.
We should consider what new questions our observations
raise. One set of issues is: By what mechanism is the
response of the CO/NO-cGMP signaling system coordi-
nated? For many years investigators have reported acute
changes in spinal cord transcription factor levels after nox-
ious formalin stimulation. Some of the identified factors
include c-fos, Fos B, c-jun, jun B, jun D and CREB [18-20].
These could potentially distribute the nociceptive signal
to multiple genes sharing particular transcription factor
consensus sequences. It need to be recognized, however,
that the time courses for mRNA expression increases were
not identical for all genes we studies. Thus we would not
necessarily expect a single mechanism or transcription fac-
tor to govern all the responses measured. In addition to
transcription factors and CO/NO-cGMP signaling system
components, many other types of molecules including
ion channels, nociceptive neurotransmitters, enzymes
and other molecules increase in spinal cord abundance
after formalin injection [21-25]. We would hypothesize
that ongoing investigation into the mechanistic basis for
these changes will reveal the involvement of a relatively
small group of signaling molecules and transcription fac-
tors which influence the expression of a large number of
genes via interaction with common promoter region ele-
ments in the involved genes. Given the level of our knowl-
edge of the murine genome and the available
computational tools, comparison of promoter region
sequences for genes responding in a similar manner to
noxious stimuli like formalin is becoming feasible.
Conclusion
Noxious inflammatory stimulation causes the increased
expression of enzymes participating at each level in the
CO/NO-cGMP signalling system. Changes in gene expres-
sion corresponding to components of this enzyme system
are blocked by the co-administration of morphine though
chronic nociceptive sensitisation can still occur. Future
studies may be directed at understanding the coordinated
CO/NO-cGMP signalling system response is achieved,
and whether other pain-related enzyme systems share this
type of multi-level response.
Methods
Animal use
All experimental protocols were reviewed and approved
by the VAPAHCS institutional animal care and use com-
mittee prior to the initiation of work. Male mice 12–14
weeks old of the C57Bl/6J strain were kept under standard
conditions with a 12 h light/dark cycle and allowed food
and water ad libitum. Mice were obtained from Jackson
Laboratories (Bar Harbor, MA) and were kept in our ani-
mal facility a minimum of 1 week prior to use in experi-
ments.
Drug administration
5% Formalin solution in 0.9% NaCl was made fresh on
the day of experimentation. To induce inflammation, 20
µl of this solution was injected subcutaneously using a
27gauge needle and a microsyringe on the dorsal surface
of both hind paws [19]. Control animals received injec-
tions of an equal volume of 0.9% NaCl. Animals also
received subcutaneous injections of 0.9% NaCl or this
vehicle containing 10 mg/kg morphine sulphate (Sigma
Chemical, St. Louis, Mo) 30 min prior to formalin injec-
tion. Previous experiments demonstrated analgesia to be
maximal within 30 minutes of morphine injection [17].
Pain models
The formalin assay was carried out as we have previously
described [2,13]. After the administration of formalin (see
Drug Administration) the mouse was placed in a clear cir-
cular enclosure 25 cm in diameter with a glass floor, and
the time spent licking the injected hind paw was meas-
ured. Phase I (0–5 min) hind paw licking was tabulated
along with phase II licking (10–40 min) by recording total
licking times in sequential 5 minute intervals.
Mechanical allodynia was assayed using nylon von Frey
filaments according to the "up-down" algorithm
described by Chaplan et al. [26] as we have used previ-
ously to detect allodynia after formalin injection [13]. In
these experiments mice were placed on wire mesh plat-
forms in clear cylindrical plastic enclosures of 10 cm
diameter. After 20 minutes of acclimation, fibers of
sequentially increasing stiffness (0.2–2 grams, 7 fibers)
were applied to the centre of the plantar surface of the
right hind paw just distal to the first set of foot pads and
left in place 5 sec. Withdrawal of the hind paw from the
fiber was scored as a response. When no response was
obtained the next stiffest fiber in the series was applied to
the same paw; if a response was obtained a less stiff fiber
was next applied. Testing proceeded in this manner until
4 fibers had been applied after the first one causing a with-
drawal response allowing the estimation of the mechani-
cal withdrawal threshold [27].Molecular Pain 2005, 1:33 http://www.molecularpain.com/content/1/1/33
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Tissue harvest for expression studies
Animals were sacrificed at specific time points by CO2
asphyxiation. Spinal cord lumbar segments (L3-S1) were
harvested by extrusion and rapid dissection at the indi-
cated times after formalin injection on a pre-chilled sur-
face. Tissue was then quick frozen in liquid nitrogen and
stored at -80°C until use.
Total RNA isolation, reverse transcription and real-time 
PCR
The isolation of RNA and quantification using real time
PCR were performed as described previously for spinal
cord samples [12,13,28]. The isolation of total RNA was
performed using the RNeasy Mini Kit (Qiagen, Valencia,
CA) according to manufacturer's instructions. The purity
and concentration was determined spectrophotometri-
cally. Subsequently, cDNA was synthesized from this total
RNA using random hexamer priming and a First Strand
cDNA Synthesis Kit (Invitrogen, Carlsbad, CA). Briefly, 1
µg of total RNA was mixed with 4 µl of 10 × RT buffer, 8
µl of 25 mM MgCl2, 4 µl 0.1 M DTT, 1 µl RNasin, 2 µl SSII
(50 u/µl), 5 µl hexomers and RNase-free water to 40 µl.
Incubation was then carried out at 42°C for 60 minutes
followed by heat inactivation at 70°C. Finally 1 µl RNase
H was added to each reaction and incubated at 37°C for
20 minutes to degrade the RNA.
For real-time PCR, reactions were conducted in a volume
of 4 µl using the Sybr Green I master kit (PE applied Bio-
systems, Foster City, CA). Briefly, 2 µl of a mixture of 2 ×
sybr green and primers (see Table 1) was loaded with 2 µl
diluted cDNA template in each well. 8 µl mineral oil was
loaded in each well to prevent loss of solution. PCR
parameters were 95°C, 5 min then [95°C, 30 s→ 60°C,
30 s→ 72°C, 60 s] for 40 cycles. Melting curves were per-
formed to document single product formation, and agar-
ose electrophoresis confirmed product size. 18 s RNA was
used as an internal control. The 18 s primers were pur-
chased from Ambion (Austin, TX). Amplification kinetics
for these products were found to be similar. The data from
real-time PCR experiments were analysed by the compar-
ative CT method. For these calculations average Ct values
from triplicate PCR reactions for CaMKIIα were normal-
ized to average Ct values for ones from 18 s from the same
cDNA preparations. The ratio of comparative expression
of each gene between the treated and untreated samples
was calculated as 2-(∆∆Ct). Ct represents threshold cycle of
PCR amplification. ∆Ct represents the difference in thresh-
old cycle between target and reference. ∆∆Ct represents
the difference between ∆Ct  (treatedsample) and ∆Ct
(untreated sample) for same gene.
Western blot analysis
We performed Western blot analysis for spinal cord sam-
ples as we have described previously [12,13,28,29]. Lum-
bar spinal cord tissue was homogenized in 56.8 mol/l Tris
buffer, pH 6.8 with 1.8% (V/V) β-mercaptoethanol, 9.1%
glycerol. The homogenate was centrifuged at 13,000 × g
for 15 min at 4°C. The supernatant was decanted from the
pellet and used for Western blot analyses. The concentra-
tion of protein in the homogenate was measured using
DC Protein Assay kit (Bio-Rad, Hercules, CA). Equal
Table 2: Summary of measured changes in spinal cord protein levels. The data presented represent the fold changes in spinal cord 
protein levels +/- SEM relative to control mice 2 and 48 hours after formalin injection. Some mice received 10 mg/kg morphine one 
time 30 min prior to formalin injection. *p < 0.05, **p < 0.01, ***p < 0.001. NRD, Not readily detected.
Gene Formalin (2 hr) Formalin (48 hr) Formalin (48 hr)+ Morphine
HO-1 1.00 +/- 0.03 1.03 +/- 0.02 1.02 +/- 0.08
HO-2 1.01 +/- 0.08 1.14 +/- 0.02* 0.92 +/- 0.09
NOS-1 1.05 +/- 0.04 2.29 +/- 0.07*** 0.84 +/- 0.13
NOS-2 1.06 +/- 0.06 2.00 +/- 0.11*** 1.00 +/- 0.13
NOS-3 1.01 +/- 0.03 1.16 +/- 0.01** 1.05 +/- 0.07
sGCα1 1.00 +/- 0.04 1.24 +/- 0.06** 1.02 +/- 0.05
sGCα2 0.99 +/- 0.03 0.96 +/- 0.01 1.09 +/- 0.03
PKG Iα 0.99 +/- 0.02 1.00 +/- 0.01 1.04 +/- 0.02
PKG Iβ 1.00 +/- 0.05 1.03 +/- 0.01 0.99 +/- 0.02
PKG II 1.01 +/- 0.05 1.17 +/- 0.01* 0.99 +/- 0.08
PDE 2 0.99 +/- 0.04 1.16 +/- 0.01* 1.06 +/- 0.06
PDE 3 NRD NRD NRD
PDE 5 0.99 +/- 0.05 1.25 +/- 0.02** 1.00 +/- 0.08Molecular Pain 2005, 1:33 http://www.molecularpain.com/content/1/1/33
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amounts of protein (50 µg) were size fractionated by SDS-
PAGE and electrotransferred onto a polyvinylidene diflu-
oride membrane. The blots were blocked overnight with
5% non-fat dry milk in tris-buffered saline with 0.5%
Tween-20 (TBST), incubated with primary antibody on a
rocking platform at 4°C for 72 hrs. Primary polyclonal
antibodies were obtained from the suppliers listed in
Table 1 and used at the indicated dilutions. After washing
in TBST, the blot was incubated 2 hrs at room temperature
in horseradish peroxidase conjugated anti-rabbit or anti-
goat antibody (diluted 1:2,000) (Chemicon, Temecula,
CA), washed again, incubated in ECL Plus chemolumines-
cence reagents and exposed to Kodak XAY-2 film. Bands
were quantified using scanning densitometry. Each blot
was then stripped and re-probed with anti-β actin anti-
bodies thus allowing normalization of expression
between samples.
Sample sizes
Experiments measuring acute and persistent pain related
behaviors used 6 mice in each of the control, formalin and
formalin plus morphine injected groups. For the quantifi-
cation of mRNA levels, each time point represents the
results from 12 mice with each resulting mRNA sample
analyzed in triplicate or quadruplicate in each of at least 2
independent real time PCR experiments. The measure-
ment of protein levels involved the use of 8 mice in each
of the control, formalin and formalin plus morphine
treated groups with homogenate samples analyzed in trip-
licate or quadruplicate on at least 2 Western blots.
Statistical analysis
Analysis of repeated parametric measures was accom-
plished using an ANOVA analysis of variance for repeated
measures followed by post-hoc t-testing. For simple com-
parisons of two means, two-tailed t-testing was per-
formed. A value of p < 0.05 was taken to be significant. All
data are presented as means +/- S.E.M. unless otherwise
noted.
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